
The Use of Betamethasone in Women at Risk of Preterm Delivery Associated With the Incidence of Neonates Respiratory Distress Syndrome (NRDS), A Systematic Review
Author(s) -
Fathi Nabila Alim,
Nadia D. Quartantri,
Rizka Ramadani
Publication year - 2022
Publication title -
kesans international journal of health and science
Language(s) - English
Resource type - Journals
eISSN - 2808-7178
pISSN - 2808-7380
DOI - 10.54543/kesans.v1i5.55
Subject(s) - betamethasone , medicine , neonatal respiratory distress syndrome , incidence (geometry) , respiratory distress , bronchopulmonary dysplasia , preterm delivery , pediatrics , pregnancy , obstetrics , gestational age , gestation , surgery , biology , physics , optics , genetics
Background : Neonatal Respiratory Disease Syndrome (NRDS) still become the most cause of neonatal’s mortality and morbidity especially in premature infants. Antenatal betamethasone has positive effect on preventing NRDS. Objectives : We sought to perform a systematic review of the use of bethametasone in women at risk of preterm delivery associated with the incidence of NRDS articles over the past fifty years. Methods: A systematic review was performed on PubMed and Scopus search term “Pediatrics” and “Pregnancy”. Results: Four articles identified between 2016 and 2019 specifically addressed for the use of betamethasone in women at risk of preterm delivery associated with the incidence of NRDS. A total 1800 patients were included in these four studies. The success rate range from 87,4% to 100%. Conclusion: Overall, the use of betamethasone in women at risk of preterm delivery decrease the incidence of respiratory distress syndrome in newborn significantly.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom